Evonile Pharma Ltd Guidance Report - SOIC x StockScans Report

as of Nov 2026

  1. Rights issue proceeds deployment - ₹600 cr for debt repayment, ₹58.2 cr for general corporate purposes in FY2027 Pending - In the rights issue Letter of Offer (October 2026), the company proposed deploying the entire Net Proceeds of ₹6,582.15 million during FY2027 - ₹6,000.00 million towards repayment or pre-payment of borrowings and ₹582.15 million for general corporate purposes, with up to ₹79.4 cr earmarked for the latter and ₹221.19 cr to follow the call money. No utilization disclosure exists yet as of the Letter of Offer date, which also confirmed no bridge loans raised.
  2. Open Offer timeline - closing by 24 June 2026, payment by 9 July 2026, post-offer announcement by 16 July 2026 Delivered - The Open Offer timeline set in the Draft Letter of Offer (filed with SEBI on 5 March 2026) was revised from 5 May 2026 to 24 June 2026 for closing, 19 May 2026 to 9 July 2026 for payment or refund, and 26 May 2026 to 16 July 2026 for the post-offer announcement. The tendering period ran June 11-24, 2026 with very minimal shares tendered, and ChrysCapital's purchase of Novartis AG's 70.68% stake at ₹860.64 per share closed on 29 July 2026.
  3. MR strength of \~900 with \~300 promoting Minipress - hiring complete by end Q3/early Q4 FY27, full field force by Q4 FY27 On track - At the Q2 FY27 call, management firmly guided an MR strength of \~900 with \~300 promoting Minipress, hiring only experienced people, to be complete "by end of Q3 or say at the most beginning of Q4" FY27 and the full field force in place by Q4 FY27; the Q1 FY27 PPT had planned 900+ members covering \~150,000 HCPs. As of the Q2 FY27 call recruitment was ongoing with management "pretty much satisfied with the pace", and Q2 FY27 employee benefit expenses rose to ₹14.4 cr from ₹5.3 cr YoY.
  4. Minipress XL acquisition - post-synergy payback of 8-9 years on ₹1,250 cr investment On track - At the Q2 FY27 call, management targeted a post-synergy payback of 8 to 9 years on the ₹1,250 crore Minipress brand acquisition, with starting EBITDA of ₹90-odd crores. Minipress XL was acquired from Pfizer during Q2 FY27 and its MAT Jul'26 revenue stood at ₹228 cr with \~63% value market share; no post-synergy EBITDA or payback read exists yet.
  5. Incremental cost run rate of \~₹40-50 cr per quarter from next quarter onwards On track - At the Q2 FY27 call, management expected an incremental cost run rate of around ₹40 crores to ₹50 crores per quarter versus a historical listed-entity run rate of ₹10-15 crores, from next quarter onwards; this was later restated as ₹45-50 cr incremental per quarter against the Q1 FY27 base of \~₹15 cr. Q2 FY27 employee benefit plus other expenses together were around ₹25.4 cr, up ₹10 cr versus the base, so the full run rate was not yet hit.
  6. Organic revenue base of \~₹600 cr doubled over next 5-6 years, acquisitions on top On track - At the Q2 FY27 call, management reiterated an organic base of close to around ₹600 crores and the intent to double it over the next 5 to 6 years with acquisitions on top, confirming "Yes" on FY28 exceeding ₹600 crores while clarifying ₹600 crores is the stabilized base. Q2 FY27 revenue was ₹56 cr and H1 FY27 was ₹160 cr, with a stabilized quarterly base of around ₹150 cr expected to be measurable by "Q4 or Q1 of FY28".
  7. Company name change within 120 days of Novartis AG exit Delivered - In the Q1 FY27 PPT, NIL stated plans to change its company name within 120 days of the Novartis AG exit as promoter, subject to relevant stakeholder approvals. Novartis AG's 70.68% stake sale to ChrysCapital closed on 29 July 2026, and the company was renamed Evonile Pharma Limited (formerly Novartis India Limited) per an announcement dated 4 November 2026, within the window.